BioCentury
ARTICLE | Clinical News

ALD-301: Additional Phase I/II data

November 23, 2009 8:00 AM UTC

Additional data from a double-blind Phase I/II trial in 21 patients showed that ALD-301 significantly improved clinical status as measured by a 0.64-point reduction from baseline to 12 weeks in the Ru...